Lite Strategy, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LITS research report →
Price Chart
About the company
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc.
- CEO
- Justin J. File
- IPO
- 2003
- Employees
- 5
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on LITS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.99M
- P/E
- -0.10
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -86.90%
- ROIC
- -20.17%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-12,269,000
- Net Income
- $-71,150,000-346.2%
- EPS
- $-2.06+13.8%
- OCF Growth
- +56.2%
- FCF Growth
- +56.2%
- 52W High
- $1.99
- 52W Low
- $0.69
- 50D MA
- $1.15
- 200D MA
- $1.07
- Beta
- 0.04
- RSI (14)
- 34
- Avg Volume
- 527.20K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MEI Pharma ended the year with $100.7 million in cash and is now focused on advancing two early-stage oncology programs, voruciclib and ME-344, after ending the planned Infinity merger.· September 26, 2023
- Cash was $100.7 million at June 30, 2023, with no debt; management said this funds operations for at least 12 months and through upcoming data readouts.
- Voruciclib remains in Phase 1, with management highlighting generally good tolerability, no significant myelosuppression, and early signs of activity in heavily pre-treated patients.
- ME-344 is being advanced in metastatic colorectal cancer with bevacizumab after prior clinical and biomarker work, including a 42-patient breast cancer window-of-opportunity study showing reduced Ki67.
- The company expects voruciclib data in early 2024 and ME-344 data in the first half of 2024.
- Revenue recognized this year was collaboration-driven and is not expected to continue into the future, according to management.
As reported on the call, MEI had $100.7 million in cash, cash equivalents and short-term investments and no outstanding debt as of June 30, 2023. Management said this cash is sufficient to fund operations for at least the next 12 months and through clinical data readouts from the ongoing and planned voruciclib and ME-344 Phase 1/1b programs. The company did not provide quarterly revenue, EPS, or gross margin figures on the call; instead, management said the recognized revenue is entirely KKC-driven collaboration revenue and is not anticipated to continue going forward. On costs, Jay File said fiscal 2023 R&D was about $52.5 million, with about $26 million specifically related to zandelisib, and that R&D should fall significantly as COASTAL and TIDAL wind down. Forward milestones: voruciclib data are expected in early calendar 2024, and ME-344 data are expected in the first half of 2024.
David Urso framed the quarter as a transition to a standalone strategy after terminating the Infinity merger agreement, saying MEI is committed to its two clinical-stage programs. His tone was constructive and optimistic, emphasizing that voruciclib and ME-344 each have novel mechanisms, clear biologic hypotheses, and meaningful market opportunities in combination with current standards of care. He repeatedly tied the company’s near-term value story to upcoming data readouts rather than to commercial execution.
Jay File kept his remarks brief and focused on liquidity and runway. He said MEI ended June 30, 2023 with $100.7 million in cash, cash equivalents and short-term investments, with no debt, and that this should fund operations for at least 12 months and through the planned clinical readouts. In response to questions, he also noted that fiscal 2023 R&D was about $52.5 million, with about $26 million tied to zandelisib, and that those expenses should continue to roll off as the related trials wind down.
Analysts focused first on runway and whether management’s ‘at least 12 months’ cash guidance was conservative; Urso said it was appropriate for the current Phase 1 plans and that further development beyond that is data-driven. Another question asked whether top-line revenue would continue; management said the revenue being recognized is collaboration revenue from KKC and is not expected to continue. On voruciclib, management said the upcoming readout should include safety, PK, biomarker data such as MCL-1 and MYC, and possibly a recommended Phase 2 dose. Analysts also pressed on ME-344’s 20% four-month PFS threshold and how it compares with historical data; management said the threshold was a floor agreed with investigators, based on regorafenib-era benchmarks, and that the readout’s meaning will depend heavily on the patients enrolled.
Management sounded encouraged by both programs’ early clinical and mechanistic data. Voruciclib has shown tolerability without significant myelosuppression and signs of activity in heavily pre-treated patients, while ME-344 has biomarker support from the breast cancer window-of-opportunity study and a clear next step in colorectal cancer. The company also has enough cash to reach the next set of readouts.
Both programs remain early and data dependent, with no pivotal-stage results or commercial revenue in sight. Management acknowledged that future development beyond the current Phase 1/1b plans is impossible to predict until data are in, and the company said collaboration revenue will not continue. R&D is also falling in part because the zandelisib program is winding down, which underscores that the pipeline is still narrow and concentrated in a few clinical bets.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.6%
- Shares Outstanding
- 29.88M
- Float Shares
- 23.19M
of shares held by institutions
39 13F filers
Buy/sell ratio 2.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.10M | ▲ 385.65K |
| Vanguard Capital Management LLC | 1.02M | 0 |
| Renaissance Technologies LLC | 966.06K | ▼ 281.29K |
| Rlh Capital LLC | 806.43K | 0 |
| Two Sigma Investments, LP | 557.01K | ▼ 57.43K |
| Geode Capital Management, LLC | 365.02K | 0 |
| Citadel Advisors LLC | 357.53K | ▼ 372.57K |
| Jane Street Group, LLC | 295.62K | ▲ 102.99K |
| Blackrock, Inc. | 270.73K | ▼ 5.10K |
| Two Sigma Advisers, LP | 204.30K | ▲ 204.30K |
| Vanguard Fiduciary Trust Co | 195.39K | 0 |
| State Street Corp | 115.02K | 0 |
Held by 22 ETFs
Biggest fund positions in LITS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Lee Charles Benjamin | other | 566,721 |
| Oct 29, 26 | Lee Charles Benjamin | other | 517,509 |
| Oct 29, 26 | Lee Charles Benjamin | other | 44 |
| Oct 29, 26 | Lee Charles Benjamin | other | 283,360 |
| Oct 8, 25 | Lee Charles Benjamin | other | 234,149 |
| Oct 29, 26 | Lee Charles Benjamin | other | 234,149 |
| Nov 17, 26 | Flynn James P | buy | 27,450 |
| Oct 22, 26 | Glover Nicholas | other | 100,000 |
| Jul 23, 25 | Glover Nicholas | buy | 1,000 |
| Jul 22, 25 | Glover Nicholas | buy | 1,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LITS coverage
Recent articles, reports, and earnings notes.
No research on LITS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LITS report →Litecoin Fell Below $50 and Sits 88% Under Its All-Time High, Twice as Far as Bitcoin. Will LTC Ever Go Back Up?
247wallst.com · Nov 12
AI Price Prediction: Grok Prices Solana, Cardano and Litecoin for 2028. Which Gains the Most?
247wallst.com · Nov 11
Lite Strategy Reports Fiscal 2027 First Quarter Financial Results
globenewswire.com · Nov 10
Litecoin Just Turned 15. Has It Kept Up With Bitcoin?
247wallst.com · Oct 17
Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
globenewswire.com · Oct 13
Stock Traders Purchase High Volume of Lite Strategy Call Options (NASDAQ:LITS)
defenseworld.net · Oct 3
Lite Strategy Reports Fiscal Year 2026 Financial Results
globenewswire.com · Sep 29
Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.